Featured
Bangladesh has entered into a deal with the Serum Institute of India (SII) to acquire 30 million doses of a potential vaccine being developed by AstraZeneca for Covid-19.SII and Bangladesh’s drugmaker Beximco Pharma signed a Memorandum of Understanding (MoU) for priority delivery of the vaccine doses.Under the deal, Beximco will purchase five milli...
Details
Background: The Gamaleya Research
Institute in Russia is testing their non-replicating viral vector COVID-19
vaccine candidate, Sputnik V (formerly Gam-COVID-Vac), in two Phase 1/2 trials.
The trials recruited about 38 participants each to receive the vaccine
candidate (NCT04436471) (NCT04437875).
Outcomes...
Pharmaceutical company AstraZeneca and
Oxford University have resumed clinical trials of their COVID-19 vaccine
candidate in the United Kingdom after a brief global pause in testing.
AstraZeneca
put a hold on its COVID-19 clinical trials worldwide this week while it
investigated an adverse reaction in...
Oxford
researchers halt vaccine trial while adverse reaction is investigated
One
of the leading covid-19 vaccine candidate trials has been voluntarily paused as
part of a standard review process triggered by a “single event of an
unexplained illness that occurred in the UK phase III trial.”
The...
Beximco Pharmaceuticals, one of
the leading drug makers of the country, announced today it will invest with
Serum Institute of India (SII) to ensure Bangladesh receives Covid-19 vaccine
on a priority basis, once approved by the regulator.
In a press statement, Beximco
Pharmaceuticals said it will make a financial contribution...
The Covid-19 vaccine candidates by University of Oxford-AstraZeneca, Moderna Inc, Pfizer Inc-BioNTech and Chinese firm Sinovac & Sinopharm are all undergoing Phase III trials at present. Oxford-AstraZeneca coronavirus vaccine price:Adar Poonawalla, CEO of Serum Institute of India, said the cost of the vaccine is estimate...
The government has permitted icddr,b to run the Phase-III trial of a coronavirus vaccine developed by Chinese biopharmaceutical company Sinovac in Bangladesh.The Bangladesh Medical Research Council (BMRC) approved the vaccine in the middle of July more than a month after the icddr,b, local partner of Sinovac, submitted an application to...
Background: Biotech Company Novavax announced in March that it has produced a stable, prefusion protein nanoparticle vaccine candidate for COVID-19. A Phase 1/2 trial evaluating NVX-CoV2373 began on 25 May. Study Design: A randomized, observer-blinded, placebo-controlled trial of 130 healthy participants 18 to 59 years of age at two s...
NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2, the virus that causes COVID-19 disease. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.NVX‑CoV2373 was created using Novavax’ recombinant nanop...
Maryland-based Novavax makes vaccines by sticking proteins onto microscopic particles. Engineered from the genetic sequence of COVID-19, we used our recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein. The company launched trials for a Covid-19 vaccine in May.Phase 1 & Phase 2 TrialIn t...
Background: mRNA-1273 was developed by Moderna based on prior
studies of related coronaviruses such as those that cause severe acute
respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A
Phase 1 trial (NCT04283461) of 105 healthy participants provided the basis for
Moderna’s investigational new drug appl...
Moderna’s mRNA vaccine technology
offers potential advantages in efficacy, speed of development, and production
scalability and reliability.
mRNA-based vaccines offer several
advantages, including:
Ability
to mimic many aspects of natural viral infections.
mRNA enters cells and is used to
produce viral antigen...
